14種抗癌藥價格下調(diào) 9月起患者或可買到

China's state medical insurance administration has lowered the procurement prices of 14 cancer drugs, asking provincial-level drug procurement platforms to follow the new standard by the end of September.

中國國家醫(yī)療保障管理部門近日降低了14種抗癌藥品的采購價格，并要求省級藥品采購平臺在9月底前遵循新標(biāo)準(zhǔn)。

The National Healthcare Security Administration said last Saturday patients are expected to be able to buy these drugs starting from September.

國家醫(yī)療保障局上周六表示，預(yù)計從九月起，患者就可以買到這些藥物了。

The decision was based on a recent circular on the adjustment of medical insurance reimbursement and procurement prices of cancer drugs.

這項決定的提出是基于最近發(fā)布的關(guān)于調(diào)整醫(yī)保對抗癌藥的免除比例和采購價格的通告。

The administration will further its guidance to make sure the new prices are implemented, inorder to allow the public to enjoy the benefits as soon as possible, a source from theadministration said.

據(jù)來自該機(jī)構(gòu)的的消息人士透露，為使大眾盡快享受到這項利益，他們將做進(jìn)一步工作，以確保新的定價可以得以實施。

 

Negotiations have been underway between the administration and pharmaceutical companiesto add more affordable cancer drugs to the country's medical insurance reimbursement list.

管理機(jī)構(gòu)和制藥企業(yè)之間的協(xié)商仍在進(jìn)行中，從而將更多的人們可負(fù)擔(dān)起的抗癌藥物加入到醫(yī)療保險補償目錄之中。

A range of drugs have been selected, with the administration confirming the producers'willingness to further negotiate. The drugs are all crucial in dealing with hematologicalneoplasms and solid tumors, and have great clinical value and bode huge benefits to patients, the administration said.

目前一些藥品已選定，正在確認(rèn)藥企是否有進(jìn)一步協(xié)商的意愿。管理機(jī)構(gòu)表示，這些藥物對治療血液腫瘤和實體固態(tài)瘤都至關(guān)重要，具有很大的臨床價值，對患者有巨大的益處。

Negotiations launched in 2017 have lowered the prices of 15 clinically-effective yet highly-priced cancer drugs such as Heceptin, Rituximab, and Bortezomib, as well as added them to the medical insurance reimbursement list.

經(jīng)過協(xié)商，15種臨床有效但價格高昂的抗癌藥物的價格在2017年進(jìn)行了下調(diào)，如赫賽汀、利妥昔單抗和硼替佐米，并將這些加入到了醫(yī)療保險報銷清單。